These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21791546)

  • 1. Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept.
    Blache C; Lequerré T; Roucheux A; Beutheu S; Dedreux I; Jacquot S; Le Loët X; Boyer O; Vittecoq O
    Rheumatology (Oxford); 2011 Oct; 50(10):1814-22. PubMed ID: 21791546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF-α therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis.
    Huang Z; Yang B; Shi Y; Cai B; Li Y; Feng W; Fu Y; Luo L; Wang L
    Cell Immunol; 2012 Sep; 279(1):25-9. PubMed ID: 23059810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs.
    Borah BJ; Huang X; Zarotsky V; Globe D
    Curr Med Res Opin; 2009 Jun; 25(6):1365-77. PubMed ID: 19425902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors.
    Aeberli D; Seitz M; Jüni P; Villiger PM
    Rheumatology (Oxford); 2005 Feb; 44(2):172-5. PubMed ID: 15509629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study.
    Szalay B; Vásárhelyi B; Cseh A; Tulassay T; Deák M; Kovács L; Balog A
    Clin Rheumatol; 2014 Feb; 33(2):175-85. PubMed ID: 23934385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells.
    Dige A; Hvas CL; Deleuran B; Kelsen J; Bendix-Struve M; Dahlerup JF; Agnholt J
    Scand J Gastroenterol; 2011 Oct; 46(10):1206-14. PubMed ID: 21793633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study.
    de la Torre I; Valor L; Nieto JC; Montoro M; Carreño L
    Reumatol Clin; 2014; 10(2):101-4. PubMed ID: 24280444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
    Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
    Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy.
    Dulic S; Vásárhelyi Z; Sava F; Berta L; Szalay B; Toldi G; Kovács L; Balog A
    Mediators Inflamm; 2017; 2017():6894374. PubMed ID: 29209104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+CD25(high)CD127(low/-) Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis.
    Kawashiri SY; Kawakami A; Okada A; Koga T; Tamai M; Yamasaki S; Nakamura H; Origuchi T; Ida H; Eguchi K
    J Rheumatol; 2011 Dec; 38(12):2517-21. PubMed ID: 21921095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy.
    McGovern JL; Nguyen DX; Notley CA; Mauri C; Isenberg DA; Ehrenstein MR
    Arthritis Rheum; 2012 Oct; 64(10):3129-38. PubMed ID: 22674488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
    Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.
    Galarraga B; Belch JJ; Pullar T; Ogston S; Khan F
    J Rheumatol; 2010 Mar; 37(3):521-8. PubMed ID: 20080919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.